Not approved
FDA (U.S.): Not approved. When proposed for compounding, the FDA noted possible immunogenicity and impurities and a lack of safety data (the proposal was withdrawn).
EMA (EU): Not approved.
In Russian observational trials: 0.5-10 mg/day subcutaneously or intramuscularly in cycles of 10-20 days. Not approved in the West.
In aged rhesus monkeys, epitalon stimulated nighttime melatonin production and normalized the daily cortisol rhythm. This is an animal study: not demonstrated in people.
View the study (preclinical) →In rats with retinal degeneration it preserved the structure and function of the retina. The authors (patent holders) describe a positive clinical effect in 90% of patients with degenerative retinal lesions, without a control group or randomization.
View the study (study) →Follow-up of 266 older people for 6-8 years treated with epithalamin and thymalin (extracts from which epitalon is derived): the authors describe fewer respiratory infections and lower mortality. Non-randomized study by the research group itself, not replicated.
See the study (observational) →Information, not medical advice. Scientific evidence reflects the quality of the studies.